Best SARMs for Muscle Growth? Top 3 Research Compounds Explained (2026 Guide)

Best SARMs for Muscle Growth Reserach: Top 3 Research Compounds Compared

Searches for the best SARMs for muscle growth often produce lists that mix genuine selective androgen receptor modulators with unrelated research compounds. This makes it difficult to understand which substances genuinely interact with the androgen receptor and which operate through completely different pathways.

RAD-140, LGD-4033 and YK-11 are three of the most frequently discussed compounds in muscle-related SARM research. However, they do not have equal classifications, mechanisms or levels of scientific evidence. RAD-140 and LGD-4033 are established non-steroidal SARMs, while YK-11 is a structurally steroidal androgen receptor partial agonist supported mainly by preliminary cellular research.

This research overview compares their mechanisms, evidence and limitations. It does not provide consumption, dosage, cycle or performance-enhancement guidance. All compounds discussed remain investigational research materials.

What Are SARMs and Why Are They Studied in Muscle Research?

SARM stands for selective androgen receptor modulator. The androgen receptor is a nuclear receptor that regulates gene transcription after being activated by a suitable molecular ligand. It is expressed across several tissue types and plays an important role in anabolic signalling, skeletal muscle biology, bone regulation and cellular differentiation.

Traditional androgen receptor agonists can activate the receptor across numerous tissues. SARMs were developed to investigate whether androgen receptor activity could be made more tissue selective. The scientific objective was to retain useful anabolic signalling in muscle and bone models while reducing activity in other androgen-responsive tissues.

A SARM binds to the androgen receptor and alters its three-dimensional conformation. This influences the recruitment of coactivator and corepressor proteins, which then affects the transcription of androgen-responsive genes. Different compounds can produce different receptor conformations, binding affinities and gene-expression profiles.

This is why the term “selective” should not be interpreted as meaning completely isolated, risk-free or active in only one tissue. Selectivity is relative and depends on factors including:

• Receptor distribution
• Ligand concentration
• Cellular environment
• Coactivator availability
• Gene-expression context
• Metabolism and exposure
• Experimental model

Muscle research frequently examines myoblast proliferation, myogenic differentiation, protein synthesis, nitrogen-related endpoints, lean-tissue measurements and the expression of regulatory factors such as MyoD, Myf5 and myogenin. Researchers may also study downstream signalling involving PI3K, Akt, mTOR and other pathways connected with cellular growth and adaptation.

The phrase “best SARMs for muscle growth” therefore oversimplifies a complicated research question. A compound that produces strong receptor activity in a cellular assay may not have equivalent evidence in a complete biological model. Likewise, a change in lean-tissue measurement does not automatically demonstrate improved strength, function or long-term safety.

A scientifically accurate comparison must examine classification, mechanism and evidence quality rather than simply labelling one product the strongest SARM.

Top 3 SARMs Associated With Muscle-Growth Research

1. RAD-140 Testolone

RAD-140, commonly called Testolone, is a non-steroidal selective androgen receptor modulator. Its chemical structure distinguishes it from steroidal androgens while allowing it to bind to and activate the androgen receptor.

RAD-140 was developed as a potent, orally bioavailable SARM and was characterised in preclinical models of anabolic and androgenic activity. Early research described tissue-selective androgen receptor activity, providing the basis for its continued investigation in muscle, bone and other androgen-responsive systems.

When RAD-140 enters an androgen-responsive cell, it binds to the androgen receptor in the cytoplasm. The receptor-ligand complex then translocates into the nucleus, where it interacts with androgen-response elements located within DNA. This can alter the transcription of genes associated with cellular differentiation, protein turnover and anabolic signalling.

The scientific interest in RAD-140 and muscle growth is therefore based on its receptor affinity and anabolic activity in preclinical models. However, the available evidence does not justify calling RAD-140 a proven muscle-building compound. Much of the research remains preclinical, and findings from cellular or animal models cannot be treated as universal outcomes.

RAD-140 also demonstrates why receptor selectivity must be described carefully. Its effects depend on the tissue, model and genes being examined. Androgen receptor activation can influence several biological systems, not only skeletal muscle.

Within a comparison of the best SARMs for muscle growth research, RAD-140 deserves inclusion because it is a genuine non-steroidal SARM with documented androgen receptor activity. Its limitation is that the evidence supporting muscle-specific outcomes is less extensive than many online rankings suggest.

View RAD-140 Testolone Research Compound at BioPlex Peptides ⟶

2. LGD-4033 Ligandrol

LGD-4033, commonly known as Ligandrol, is a non-steroidal SARM with high affinity for the androgen receptor. Of the three compounds compared in this article, LGD-4033 has some of the clearest published evidence connecting its activity with lean-tissue research endpoints.

Androgen receptor activation by LGD-4033 can influence transcriptional programmes associated with anabolic signalling. Once the ligand-receptor complex enters the nucleus, it interacts with androgen-responsive DNA sequences and modifies the expression of downstream genes.

Published research has examined LGD-4033 in relation to lean body mass, strength measurements, pharmacokinetics, hormonal markers and lipid-related variables. A controlled investigation reported a dose-related increase in lean body mass over a short study period. However, corresponding improvements in strength were not clearly established.

That distinction is important for SEO content discussing the best SARM for muscle growth. Lean mass, muscle size, physical strength and functional performance are related but separate endpoints. An increase in one measurement does not automatically establish improvement across all four.

The same investigation also documented changes in endocrine and lipid markers. This is a reminder that tissue selectivity does not remove wider biological activity. It would be inaccurate to describe LGD-4033 as side-effect free or entirely muscle selective.

Compared with RAD-140 and YK-11, LGD-4033 has a stronger published foundation for discussion of lean-tissue outcomes. It should not, however, be declared universally best. The research remains limited in duration and scale, and further work is required to establish longer-term effects and functional relevance.

LGD-4033 ranks strongly within this comparison because it is correctly classified as a SARM, has high androgen receptor affinity and has been examined using measurable body-composition endpoints.

View LGD-4033 Ligandrol Research Compound at BioPlex Peptides ⟶

3. YK-11 Myostine

YK-11 is frequently included in lists of the strongest SARMs for muscle growth, but its classification requires more explanation. Unlike RAD-140 and LGD-4033, YK-11 possesses a steroidal molecular structure. Research describes it as a partial androgen receptor agonist and gene-selective modulator.

A partial agonist binds to a receptor but does not necessarily produce the same maximum response as a full agonist. YK-11 has been shown to promote androgen receptor nuclear translocation while producing a distinctive pattern of receptor activation.

The interest surrounding YK-11 largely comes from cellular research examining myogenic differentiation and follistatin expression. Follistatin is a binding protein involved in regulating members of the transforming growth factor beta superfamily. Its relationship with activin and myostatin pathways makes it relevant to muscle-cell development and differentiation research.

In C2C12 myoblast experiments, YK-11 increased the expression of myogenic regulatory factors including MyoD, Myf5 and myogenin. The same research associated YK-11 with increased follistatin expression. When follistatin activity was blocked experimentally, the observed YK-11-related myogenic response was reduced.

These findings provide an interesting mechanistic basis for further study, but they are frequently exaggerated online. Cellular findings do not establish whole-system outcomes, comparative potency or long-term safety. There is not enough evidence to state that YK-11 blocks myostatin completely or that it is proven to produce greater muscle growth than conventional SARMs.

YK-11 belongs in this top-three comparison because it is strongly associated with myogenic research and androgen receptor activity. Nevertheless, it has the weakest overall evidence base of the three. It should be described as a steroidal SARM-associated research compound or androgen receptor partial agonist, rather than treated as identical to RAD-140 and LGD-4033.

View YK-11 Myostine Research Compound at BioPlex Peptides ⟶

 

RAD-140 vs LGD-4033 vs YK-11

Although all three compounds are associated with androgen receptor and muscle research, they differ significantly.

 

RAD-140 has a clear non-steroidal SARM classification and documented receptor selectivity, but muscle-related evidence remains primarily preclinical.

LGD-4033 has been examined more directly against lean-tissue and body-composition measurements. This gives it the strongest evidence position within this particular comparison, although the available research remains limited.

YK-11 has an interesting cellular mechanism involving androgen receptor activation and follistatin expression. However, it cannot be ranked as the strongest compound based only on laboratory cell findings.

Consequently, the answer changes according to the question being asked:

• LGD-4033 has the strongest direct evidence for lean-tissue endpoints among these three.
• RAD-140 has a well-established non-steroidal SARM classification and potent preclinical androgen receptor activity.
• YK-11 presents the most distinctive preliminary myogenic mechanism but has the least complete evidence.

This is more accurate than assigning a single winner without considering the type and quality of the research.

 

Which Products Are Called SARMs but Are Not SARMs?

Online SARM lists frequently include MK-677, SR-9009 and SR-9011. These compounds may appear beside SARMs in research catalogues, but they are not selective androgen receptor modulators.

Is MK-677 Ibutamoren a SARM?

No. MK-677, also known as Ibutamoren, does not produce its principal effects by selectively modulating the androgen receptor.

MK-677 is a non-peptide growth hormone secretagogue and ghrelin receptor agonist. It interacts with the growth hormone secretagogue receptor, also known as GHS-R1a. This can influence growth-hormone signalling and downstream insulin-like growth factor pathways within experimental models.

Because MK-677 is often discussed alongside muscle and body-composition research, it is regularly placed in SARM articles and product categories. Its association with similar research interests does not change its pharmacological classification.

View MK-677 Ibutamoren Research Compound at BioPlex Peptides ⟶

Is SR-9009 Stenabolic a SARM?

No. SR-9009 is commonly described as a synthetic REV-ERB agonist. REV-ERB proteins are nuclear receptors involved in circadian regulation, cellular metabolism, mitochondrial activity and transcriptional control.

SR-9009 does not qualify as a SARM because selective androgen receptor modulation is not its defining mechanism. Its presence in SARM collections reflects overlapping research interest rather than membership of the same compound class.

Questions have also been raised in published research about its pharmacology and whether some observed cellular effects occur independently of REV-ERB. It should therefore be presented cautiously as an experimental REV-ERB-associated compound.

View SR-9009 Stenabolic Research Compound at BioPlex Peptides ⟶

Is SR-9011 a SARM?

SR-9011 is also associated with REV-ERB research rather than selective androgen receptor modulation. It is studied in relation to circadian transcription, metabolic gene expression and cellular energy regulation.

Like SR-9009, SR-9011 may appear within the broader commercial SARM category because researchers interested in performance-related, metabolic or body-composition pathways often compare these products. Scientifically, it should be labelled a related research compound and not a genuine SARM.

View SR-9011 REV-ERB Agonist Research Compound at BioPlex Peptides ⟶

 

Is There Scientifically a Best SARM for Muscle Growth?

There is no scientifically established single best SARM for muscle growth.

The word “best” depends on the endpoint being measured. A researcher could be comparing androgen receptor affinity, lean-tissue change, myoblast differentiation, gene expression, strength, functional performance or tissue selectivity. These measurements are not interchangeable.

The existing research also differs substantially between compounds. LGD-4033 has published evidence involving lean-tissue measurements. RAD-140 has documented potency and selectivity across preclinical models. YK-11 has intriguing cellular evidence connected with myogenic differentiation and follistatin, but its wider evidence base is much smaller.

It would therefore be misleading to make claims such as:

• One SARM guarantees the greatest muscle growth
• YK-11 completely blocks myostatin
• Selectivity means no wider biological effects
• Lean-tissue changes automatically produce greater strength
• Research findings establish safe performance-enhancement practices

A more defensible conclusion is that LGD-4033 currently has the clearest direct evidence for lean-tissue endpoints among the three compounds compared. RAD-140 remains important for selective androgen receptor research, while YK-11 represents a more preliminary and mechanistically distinctive area of myogenic investigation.

None of these findings creates a consumption recommendation. SARMs remain investigational compounds, and their appearance in laboratory research should not be confused with approval as medicines, dietary supplements or sports products. SARMs and related anabolic agents are also prohibited in regulated sport.

Conclusion

The search for the best SARMs for muscle growth produces a large amount of oversimplified and inaccurate information. Genuine comparison requires more than ranking products according to reputation or claimed strength. Each compound must be assessed according to its chemical classification, biological target, experimental model and quality of evidence.

RAD-140 and LGD-4033 are genuine non-steroidal selective androgen receptor modulators. Both interact with the androgen receptor and are studied in relation to tissue-selective anabolic signalling. LGD-4033 has the clearest published evidence involving lean-tissue measurements, while RAD-140 has a strong preclinical foundation as a potent and tissue-selective androgen receptor modulator.

YK-11 is more difficult to classify. It has a steroidal structure and functions as an androgen receptor partial agonist. Preliminary cellular research links it with follistatin expression and myogenic differentiation, but this evidence does not establish it as the strongest SARM or prove wider muscle-growth outcomes.

MK-677, SR-9009 and SR-9011 should not be called SARMs. MK-677 acts primarily through the ghrelin receptor, while SR-9009 and SR-9011 are associated with REV-ERB research. They may share overlapping research themes, but they do not share the defining mechanism of a selective androgen receptor modulator.

The most accurate answer is therefore that no compound is scientifically established as the universal best SARM for muscle growth. LGD-4033 has the strongest direct lean-tissue evidence within this comparison, RAD-140 offers significant preclinical androgen receptor research, and YK-11 presents an interesting but much less established myogenic mechanism.